Copyright © 2012 Mohammad Javad Fattahi and Abbas Mirshafiey. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

1. R. C. Lawrence, C. G. Helmick, F. C. Arnett et al., et al., “Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States,” Arthritis & Rheumatism, vol. 41, no. 5, pp. 778–799, 1998.
2. A. J. Silman and J. E. Pearson, “Epidemiology and genetics of rheumatoid arthritis,” Arthritis Research, vol. 4, supplement 3, pp. S265–S272, 2002.
3. J. S. Smolen and G. Steiner, “Therapeutic strategies for rheumatoid arthritis,” Nature Reviews Drug Discovery, vol. 2, no. 6, pp. 473–488, 2003. View at Publisher · View at Google Scholar · View at Scopus
4. J. R. O'Dell, J. S. Smolen, D. Aletaha, D. R. Robinson, and E. W. Saint Clair, “Rheumatoid arthritis,” in A Clinician's Pearls and Myths in Rheumatology, J. H. Stone, Ed., pp. 1–13, Springer, London, UK, 2010.
5. L. C. Huber, O. Distler, I. Tarner, R. E. Gay, S. Gay, and T. Pap, “Synovial fibroblasts: key players in rheumatoid arthritis,” Rheumatology, vol. 45, no. 6, pp. 669–675, 2006. View at Publisher · View at Google Scholar · View at Scopus
6. J. B. Imboden, “The immunopathogenesis of rheumatoid arthritis,” Annual Review of Pathology, vol. 4, pp. 417–434, 2009. View at Publisher · View at Google Scholar · View at Scopus
7. R. De Vries, “Genetics of rheumatoid arthritis: time for a change!,” Current Opinion in Rheumatology, vol. 23, no. 3, pp. 227–232, 2011. View at Publisher · View at Google Scholar · View at Scopus
8. S. Eyre, A. Barton, N. Shephard et al., “Investigation of susceptibility loci identified in the UK rheumatoid arthritis whole-genome scan in a further series of 217 UK affected sibling pairs,” Arthritis and Rheumatism, vol. 50, no. 3, pp. 729–735, 2004. View at Publisher · View at Google Scholar · View at Scopus
9. D. Jawaheer, M. F. Seldin, C. I. Amos et al., “Screening the genome for rheumatoid arthritis susceptibility genes: a replication study and combined analysis of 512 multicase families,” Arthritis and Rheumatism, vol. 48, no. 4, pp. 906–916, 2003. View at Publisher · View at Google Scholar · View at Scopus
10. A. Doncarli, G. Chiocchia, L. M. Stasiuk et al., “A recurrent valpha17/vbeta10 TCR-expressing T cell clone is involved in the pathogenicity of collagen-induced arthritis in DBA/1 mice,” European Journal of Immunology, vol. 29, no. 11, pp. 3636–3642, 1999.
11. G. E. Osman, M. Toda, O. Kanagawa, and L. E. Hood, “Characterization of the T cell receptor repertoire causing collagen arthritis in mice,” Journal of Experimental Medicine, vol. 177, no. 2, pp. 387–395, 1993. View at Scopus
12. H. Källberg, L. Padyukov, R. M. Plenge et al., “Gene-gene and gene-environment interactions involving HLA-BRB1, PTPN22, and smoking in two subsets of rheumatoid arthritis,” American Journal of Human Genetics, vol. 80, no. 5, pp. 867–875, 2007. View at Publisher · View at Google Scholar · View at Scopus
13. L. Klareskog, L. Padyukov, J. Lorentzen, and L. Alfredsson, “Mechanisms of disease: genetic susceptibility and environmental triggers in the development of rheumatoid arthritis,” Nature Clinical Practice Rheumatology, vol. 2, no. 8, pp. 425–433, 2006. View at Publisher · View at Google Scholar · View at Scopus
14. G. J. Tobón, P. Youinou, and A. Saraux, “The environment, geo-epidemiology, and autoimmune disease: rheumatoid arthritis,” Autoimmunity Reviews, vol. 9, no. 5, pp. A288–A292, 2010. View at Publisher · View at Google Scholar · View at Scopus
15. M. M. J. Nielen, D. Van Schaardenburg, H. W. Reesink et al., “Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors,” Arthritis and Rheumatism, vol. 50, no. 2, pp. 380–386, 2004. View at Publisher · View at Google Scholar · View at Scopus
16. M. Kuligowska and G. Odrowaz-Sypniewska, “Role of interleukin-17 in cartilage and bone destruction in rheumatoid arthritis,” Ortopedia, Traumatologia, Rehabilitacja, vol. 6, no. 2, pp. 235–241, 2004.
17. J. Zwerina, K. Redlich, G. Schett, and J. S. Smolen, “Pathogenesis of rheumatoid arthritis: targeting cytokines,” Annals of the New York Academy of Sciences, vol. 1051, pp. 716–729, 2005. View at Publisher · View at Google Scholar · View at Scopus
18. T. Shimizu, “Lipid mediators in health and disease: enzymes and receptors as therapeutic targets for the regulation of immunity and inflammation,” Annual Review of Pharmacology and Toxicology, vol. 49, pp. 123–150, 2009. View at Publisher · View at Google Scholar · View at Scopus
19. A. N. Hata and R. M. Breyer, “Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation,” Pharmacology and Therapeutics, vol. 103, no. 2, pp. 147–166, 2004. View at Publisher · View at Google Scholar · View at Scopus
20. D. Milatovic, T. J. Montine, and M. Aschner, “Prostanoid signaling: dual role for prostaglandin E2 in neurotoxicity,” NeuroToxicology, vol. 32, no. 3, pp. 312–319, 2011. View at Publisher · View at Google Scholar · View at Scopus
21. C. A. Rouzer and L. J. Marnett, “Cyclooxygenases: structural and functional insights,” Journal of Lipid Research, vol. 50, pp. S29–S34, 2009. View at Publisher · View at Google Scholar · View at Scopus
22. S. Hayashi, N. Ueno, A. Murase, Y. Nakagawa, and J. Takada, “Novel acid-type cyclooxygenase-2 inhibitors: design, synthesis, and structure-activity relationship for anti-inflammatory drug,” European Journal of Medicinal Chemistry, vol. 50, pp. 179–195, 2012.
23. G. A. FitzGerald and C. Patrono, “The coxibs, selective inhibitors of cyclooxygenase-2,” The New England Journal of Medicine, vol. 345, no. 6, pp. 433–442, 2001. View at Publisher · View at Google Scholar · View at Scopus
24. R. M. Breyer, C. K. Bagdassarian, S. A. Myers, and M. D. Breyer, “Prostanoid receptors: subtypes and signaling,” Annual Review of Pharmacology and Toxicology, vol. 41, pp. 661–690, 2001. View at Publisher · View at Google Scholar · View at Scopus
25. H. Hirai, K. Tanaka, O. Yoshie et al., “Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2,” Journal of Experimental Medicine, vol. 193, no. 2, pp. 255–261, 2001. View at Publisher · View at Google Scholar · View at Scopus
26. L. J. Crofford, R. L. Wilder, A. P. Ristimaki et al., “Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues. Effects of interleukin-1β, phorbol ester, and corticosteroids,” Journal of Clinical Investigation, vol. 93, no. 3, pp. 1095–1101, 1994. View at Scopus
27. A. M. Pulichino, S. Rowland, T. Wu et al., “Prostacyclin antagonism reduces pain and inflammation in rodent models of hyperalgesia and chronic arthritis,” Journal of Pharmacology and Experimental Therapeutics, vol. 319, no. 3, pp. 1043–1050, 2006. View at Publisher · View at Google Scholar · View at Scopus
28. S. Saito, H. Tsuda, and T. Michimata, “Prostaglandin D2 and reproduction,” American Journal of Reproductive Immunology, vol. 47, no. 5, pp. 295–302, 2002. View at Publisher · View at Google Scholar · View at Scopus
29. S. P. Khanapure, D. S. Garvey, D. R. Janero, and L. G. Letts, “Eicosanoids in inflammation: biosynthesis, pharmacology, and therapeutic frontiers,” Current Topics in Medicinal Chemistry, vol. 7, no. 3, pp. 311–340, 2007. View at Publisher · View at Google Scholar · View at Scopus
30. M. Murakami, K. Nakashima, D. Kamei et al., “Cellular prostaglandin E2 production by membrane-bound prostaglandin E synthase-2 via both cyclooxygenases-1 and -2,” The Journal of Biological Chemistry, vol. 278, no. 39, pp. 37937–37947, 2003. View at Publisher · View at Google Scholar · View at Scopus
31. D. W. Gilroy, P. R. Colville-Nash, D. Willis, J. Chivers, M. J. Paul-Clark, and D. A. Willoughby, “Inducible cyclooxygenase may have anti-inflammatory properties,” Nature Medicine, vol. 5, no. 6, pp. 698–701, 1999. View at Publisher · View at Google Scholar · View at Scopus
32. K. Tanaka, H. Hirai, S. Takano, M. Nakamura, and K. Nagata, “Effects of prostaglandin D2 on helper T cell functions,” Biochemical and Biophysical Research Communications, vol. 316, no. 4, pp. 1009–1014, 2004. View at Publisher · View at Google Scholar · View at Scopus
33. D. Egg, “Concentration of prostaglandins D2, E2, F(2α), 6-keto-F(1α) and thromboxane B2 in synovial fluid from patients with inflammatory joint disorders and osteoarthritis,” Zeitschrift fur Rheumatologie, vol. 43, no. 2, pp. 89–96, 1984. View at Scopus
34. M. A. Gallant, R. Samadfam, J. A. Hackett, J. Antoniou, J. L. Parent, and A. J. De Brum-Fernandes, “Production of prostaglandin D2 by human osteoblasts and modulation of osteoprotegerin, RANKL, and cellular migration by DP and CRTH2 receptors,” Journal of Bone and Mineral Research, vol. 20, no. 4, pp. 672–681, 2005. View at Publisher · View at Google Scholar · View at Scopus
35. P. Pietila, E. Moilanen, and E. Seppala, “Differences in the production of arachidonic acid metabolites between healthy and rheumatic synovial fibroblasts in vitro. A preliminary study,” Scandinavian Journal of Rheumatology, vol. 13, no. 3, pp. 243–246, 1984. View at Scopus
36. A. De Paulis, I. Marinò, A. Ciccarelli et al., “Human synovial mast cells: I. Ultrastructural in situ and in vitro immunologic characterization,” Arthritis and Rheumatism, vol. 39, no. 7, pp. 1222–1233, 1996. View at Publisher · View at Google Scholar · View at Scopus
37. B. Relić, V. Benoit, N. Franchimont et al., “15-Deoxy-Δ12,14-prostaglandin J2 inhibits bay 11-7085-induced sustained extracellular signal-regulated kinase phosphorylation and apoptosis in human articular chondrocytes and synovial fibroblasts,” The Journal of Biological Chemistry, vol. 279, no. 21, pp. 22399–22403, 2004. View at Publisher · View at Google Scholar · View at Scopus
38. M. Jakob, O. Démarteau, R. Suetterlin, M. Heberer, and I. Martin, “Chondrogenesis of expanded adult human articular chondrocytes is enhanced by specific prostaglandins,” Rheumatology, vol. 43, no. 7, pp. 852–857, 2004. View at Publisher · View at Google Scholar · View at Scopus
39. N. Zayed, H. Afif, N. Chabane et al., “Inhibition of interleukin-1β-induced matrix metalloproteinases 1 and 13 production in human osteoarthritic chondrocytes by prostaglandin D 2,” Arthritis and Rheumatism, vol. 58, no. 11, pp. 3530–3540, 2008. View at Publisher · View at Google Scholar · View at Scopus
40. N. Zayed, X. Li, N. Chabane et al., “Increased expression of lipocalin-type prostaglandin D2 synthase in osteoarthritic cartilage,” Arthritis Research and Therapy, vol. 10, no. 6, article no. R146, 2008. View at Publisher · View at Google Scholar · View at Scopus
41. W. T. Schaiff, M. G. Carlson, S. D. Smith, R. Levy, D. M. Nelson, and Y. Sadovsky, “Peroxisome proliferator-activated receptor-γ modulates differentiation of human trophoblast in a ligand-specific manner,” Journal of Clinical Endocrinology and Metabolism, vol. 85, no. 10, pp. 3874–3881, 2000. View at Scopus
42. B. M. Forman, P. Tontonoz, J. Chen, R. P. Brun, B. M. Spiegelman, and R. M. Evans, “15-deoxy-Δ12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ,” Cell, vol. 83, no. 5, pp. 803–812, 1995. View at Scopus
43. S. G. Trivedi, J. Newson, R. Rajakariar et al., “Essential role for hematopoietic prostaglandin D2 synthase in the control of delayed type hypersensitivity,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 13, pp. 5179–5184, 2006. View at Publisher · View at Google Scholar · View at Scopus
44. Z. Z. Shan, K. Masuko-Hongo, S. M. Dai, H. Nakamura, T. Kato, and K. Nishioka, “A potential role of 15-deoxy-Δ12,14-prostaglandin J2 for induction of human articular chondrocyte apoptosis in arthritis,” The Journal of Biological Chemistry, vol. 279, no. 36, pp. 37939–37950, 2004. View at Publisher · View at Google Scholar · View at Scopus
45. H. Fahmi, J. A. Di Battista, J. P. Pelletier, F. Mineau, P. Ranger, and J. Martel-Pelletier, “Peroxisome proliferator—activated receptor gamma activators inhibit interleukin-1beta-induced nitric oxide and matrix metalloproteinase 13 production in human chondrocytes,” Arthritis & Rheumatism, vol. 44, no. 3, pp. 595–607, 2001.
46. M. Ricote, A. C. Li, T. M. Willson, C. J. Kelly, and C. K. Glass, “The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation,” Nature, vol. 391, no. 6662, pp. 79–82, 1998. View at Publisher · View at Google Scholar · View at Scopus
47. C. Jiang, A. T. Ting, and B. Seed, “PPAR-γ agonists inhibit production of monocyte inflammatory cytokines,” Nature, vol. 391, no. 6662, pp. 82–86, 1998. View at Publisher · View at Google Scholar · View at Scopus
48. K. Bordji, J. P. Grillasca, J. N. Gouze et al., “Evidence for the presence of peroxisome proliferator-activated receptor (PPAR) α and γ and retinoid Z receptor in cartilage. PPArγ activation modulates the effects of interleukin-1β on rat chondrocytes,” The Journal of Biological Chemistry, vol. 275, no. 16, pp. 12243–12250, 2000. View at Publisher · View at Google Scholar · View at Scopus
49. F. Zhu, P. Wang, A. Kontrogianni-Konstantopoulos, and K. Konstantopoulos, “Prostaglandin (PG)D(2) and 15-deoxy-Delta(12,14)-PGJ(2), but not PGE(2), mediate shear-induced chondrocyte apoptosis via protein kinase A-dependent regulation of polo-like kinases,” Cell Death and Differentiation, vol. 17, no. 8, pp. 1325–1334, 2010. View at Publisher · View at Google Scholar · View at Scopus
50. J. Martel-Pelletier, J. P. Pelletier, and H. Fahmi, “Cyclooxygenase-2 and prostaglandins in articular tissues,” Seminars in Arthritis and Rheumatism, vol. 33, no. 3, pp. 155–167, 2003. View at Publisher · View at Google Scholar · View at Scopus
51. D. Claveau, M. Sirinyan, J. Guay et al., “Microsomal prostaglandin E synthase-1 is a major terminal synthase that is selectively up-regulated during cyclooxygenase-2-dependent prostaglandin E2 production in the rat adjuvant-induced arthritis model,” Journal of Immunology, vol. 170, no. 9, pp. 4738–4744, 2003. View at Scopus
52. J. Akaogi, T. Nozaki, M. Satoh, and H. Yamada, “Role of PGE2 and EP receptors in the pathogenesis of rheumatoid arthritis and as a novel therapeutic strategy,” Endocrine, Metabolic and Immune Disorders - Drug Targets, vol. 6, no. 4, pp. 383–394, 2006. View at Scopus
53. K. Gudis and C. Sakamoto, “The role of cyclooxygenase in gastric mucosal protection,” Digestive Diseases and Sciences, vol. 50, supplement 1, pp. S16–S23, 2005. View at Publisher · View at Google Scholar · View at Scopus
54. N. Tanikawa, Y. Ohmiya, H. Ohkubo et al., “Identification and characterization of a novel type of membrane-associated prostaglandin E synthase,” Biochemical and Biophysical Research Communications, vol. 291, no. 4, pp. 884–889, 2002. View at Publisher · View at Google Scholar · View at Scopus
55. T. Tanioka, Y. Nakatani, N. Semmyo, M. Murakami, and I. Kudo, “Molecular identification of cytosolic prostaglandin E2 synthase that is functionally coupled with cyclooxygenase-1 in immediate prostaglandin E2 biosynthesis,” The Journal of Biological Chemistry, vol. 275, no. 42, pp. 32775–32782, 2000. View at Scopus
56. H. Sano, “The role of lipid mediators in the pathogenesis of rheumatoid arthritis,” Inflamation and Regeneration, vol. 31, no. 2, pp. 151–156, 2011.
57. C. Bombardier, L. Laine, A. Reicin et al., “Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis,” The New England Journal of Medicine, vol. 343, no. 21, pp. 1520–1528, 2000. View at Publisher · View at Google Scholar · View at Scopus
58. B. F. McAdam, F. Catella-Lawson, I. A. Mardini, S. Kapoor, J. A. Lawson, and G. A. FitzGerald :, “Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 1, pp. 272–277, 1999.
59. M. Abramovitz, M. Adam, Y. Boie et al., “The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs,” Biochimica et Biophysica Acta, vol. 1483, no. 2, pp. 285–293, 2000. View at Publisher · View at Google Scholar · View at Scopus
60. Y. Sugimoto and S. Narumiya, “Prostaglandin E receptors,” The Journal of Biological Chemistry, vol. 282, no. 16, pp. 11613–11617, 2007. View at Publisher · View at Google Scholar · View at Scopus
61. E. Ricciotti and G. A. FitzGerald, “Prostaglandins and inflammation,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 31, no. 5, pp. 986–1000, 2011.
62. T. Honda, E. Segi-Nishida, Y. Miyachi, and S. Narumiya, “Prostacyclin-IP signaling and prostaglandin E2-EP2/EP4 signaling both mediate joint inflammation in mouse collagen-induced arthritis,” Journal of Experimental Medicine, vol. 203, no. 2, pp. 325–335, 2006. View at Publisher · View at Google Scholar · View at Scopus
63. J. L. Stock, K. Shinjo, J. Burkhardt et al., “The prostaglandin E2 EP1 receptor mediates pain perception and regulates blood pressure,” Journal of Clinical Investigation, vol. 107, no. 3, pp. 325–331, 2001. View at Scopus
64. T. Minami, H. Nakano, T. Kobayashi et al., “Characterization of EP receptor subtypes responsible for prostaglandin E2-induced pain responses by use of EP1 and EP3 receptor knockout mice,” British Journal of Pharmacology, vol. 133, no. 3, pp. 438–444, 2001. View at Scopus
65. C. Yao, D. Sakata, Y. Esaki et al., “Prostaglandin E2-EP4 signaling promotes immune inflammation through TH1 cell differentiation and TH17 cell expansion,” Nature Medicine, vol. 15, no. 6, pp. 633–640, 2009. View at Publisher · View at Google Scholar · View at Scopus
66. J. M. McCoy, J. R. Wicks, and L. P. Audoly, “The role of prostaglandin E2 receptors in the pathogenesis of rheumatoid arthritis,” Journal of Clinical Investigation, vol. 110, no. 5, pp. 651–658, 2002. View at Publisher · View at Google Scholar · View at Scopus
67. A. Haddad, G. Flint-Ashtamker, W. Minzel, R. Sood, G. Rimon, and L. Barki-Harrington, “Prostaglandin EP1 receptor down-regulates expression of cyclooxygenase-2 by facilitating its proteasomal degradation,” The Journal of Biological Chemistry, vol. 287, no. 21, pp. 17214–17223, 2012.
68. M. Miwa, R. Saura, S. Hirata, Y. Hayashi, K. Mizuno, and H. Itoh, “Induction of apoptosis in bovine articular chondrocyte by prostaglandin E2 through cAMP-dependent pathway,” Osteoarthritis and Cartilage, vol. 8, no. 1, pp. 17–24, 2000. View at Publisher · View at Google Scholar · View at Scopus
69. F. Pica, O. Franzese, C. D'Onofrio, E. Bonmassar, C. Favalli, and E. Garaci, “Prostaglandin E2 induces apoptosis in resting immature and mature human lymphocytes: a c-Myc-dependent and Bcl-2-independent associated pathway,” Journal of Pharmacology and Experimental Therapeutics, vol. 277, no. 3, pp. 1793–1800, 1996. View at Scopus
70. B. O. Porter and T. R. Malek, “Prostaglandin E2 inhibits T cell activation-induced apoptosis and Fas-mediated cellular cytotoxicity by blockade of Fas-ligand induction,” European Journal of Immunology, vol. 29, no. 7, pp. 2360–2365, 1999.
71. T. Aoyama, B. Liang, T. Okamoto et al., “PGE2 signal through EP2 promotes the growth of articular chondrocytes,” Journal of Bone and Mineral Research, vol. 20, no. 3, pp. 377–389, 2005. View at Publisher · View at Google Scholar · View at Scopus
72. M. Attur, H. E. Al-Mussawir, J. Patel et al., “Prostaglandin E2 exerts catabolic effects in osteoarthritis cartilage: evidence for signaling via the EP4 receptor,” Journal of Immunology, vol. 181, no. 7, pp. 5082–5088, 2008. View at Scopus
73. S. Otsuka, T. Aoyama, M. Furu et al., “PGE2 signal via EP2 receptors evoked by a selective agonist enhances regeneration of injured articular cartilage,” Osteoarthritis and Cartilage, vol. 17, no. 4, pp. 529–538, 2009. View at Publisher · View at Google Scholar · View at Scopus
74. P. Clark, S. E. Rowland, D. Denis et al., “MF498 [N-{[4-(5,9-dethoxy-6-oxo-6,8-dihydro-7H-yrrolo[3,4-g]quinolin-7-yl)- 3-methylbenzyl]sulfonyl}-2-(2-methoxyphenyl)acetamide], a selective E prostanoid receptor 4 antagonist, relieves joint inflammation and pain in rodent models of rheumatoid and osteoarthritis,” Journal of Pharmacology and Experimental Therapeutics, vol. 325, no. 2, pp. 425–434, 2008. View at Publisher · View at Google Scholar · View at Scopus
75. P. F. Gomez, M. H. Pillinger, M. Attur et al., “Resolution of inflammation: prostaglandin E2 dissociates nuclear trafficking of individual NF-κB subunits (p65, p50) in stimulated rheumatoid synovial fibroblasts,” Journal of Immunology, vol. 175, no. 10, pp. 6924–6930, 2005. View at Scopus
76. J. Stitham, C. Midgett, K. A. Martin, and J. Hwa, “Prostacyclin: an inflammatory paradox,” Frontiers in Pharmacology, vol. 2, p. 24, 2011.
77. X. de Leval, J. Hanson, J. L. David, B. Masereel, B. Pirotte, and J. M. Dogné, “New developments on thromboxane and prostacyclin modulators part 1: prostacyclin modulators,” Current Medicinal Chemistry, vol. 11, no. 10, pp. 1243–1252, 2004. View at Scopus
78. Y. Boie, T. H. Rushmore, A. Darmon-Goodwin et al., “Cloning and expression of a cDNA for the human prostanoid IP receptor,” The Journal of Biological Chemistry, vol. 269, no. 16, pp. 12173–12178, 1994. View at Scopus
79. Y. Sugimoto, K. Y. Hasumoto, T. Namba et al., “Cloning and expression of a cDNA for mouse prostaglandin F receptor,” The Journal of Biological Chemistry, vol. 269, no. 2, pp. 1356–1360, 1994. View at Scopus
80. R. L. Hébert, T. O'Connor, C. Neville, K. D. Burns, O. Laneuville, and L. N. Peterson, “Prostanoid signaling, localization, and expression of IP receptors in rat thick ascending limb cells,” American Journal of Physiology, vol. 275, no. 6, pp. F904–F914, 1998. View at Scopus
81. L. Hyunjung and S. K. Dey, “Minireview: a novel pathway of prostacyclin signaling—hanging out with nuclear receptors,” Endocrinology, vol. 143, no. 9, pp. 3207–3210, 2002. View at Publisher · View at Google Scholar · View at Scopus
82. Z. Jaffar, K. S. Wan, and K. Roberts, “A key role for prostaglandin I2 in limiting lung mucosal Th2, but not Th1, responses to inhaled allergen,” Journal of Immunology, vol. 169, no. 10, pp. 5997–6004, 2002. View at Scopus
83. M. J. Brodie, C. N. Hensby, A. Parke, and D. Gordon, “Is prostacyclin the major pro-inflammatory prostanoid in joint fluid?” Life Sciences, vol. 27, no. 7, pp. 603–608, 1980. View at Publisher · View at Google Scholar · View at Scopus
84. S. L. Dorris and R. S. Peebles Jr., “PGI(2) as a regulator of inflammatory diseases,” Mediators of Inflammation, vol. 2012, Article ID 926968, 9 pages, 2012. View at Publisher · View at Google Scholar
85. K. R. Bley, A. Bhattacharya, D. V. Daniels et al., “RO1138452 and RO3244794: characterization of structurally distinct, potent and selective IP (prostacyclin) receptor antagonists,” British Journal of Pharmacology, vol. 147, no. 3, pp. 335–345, 2006. View at Publisher · View at Google Scholar · View at Scopus
86. K. Watanabe, “Prostaglandin F synthase,” Prostaglandins and Other Lipid Mediators, vol. 68-69, pp. 401–407, 2002. View at Publisher · View at Google Scholar · View at Scopus
87. Y. Sugimoto, K. Y. Hasumoto, T. Namba et al., “Cloning and expression of a cDNA for mouse prostaglandin F receptor,” The Journal of Biological Chemistry, vol. 269, no. 2, pp. 1356–1360, 1994. View at Scopus
88. K. L. Pierce, H. Fujino, D. Srinivasan, and J. W. Regan, “Activation of FP prostanoid receptor isoforms leads to rho-mediated changes in cell morphology and in the cell cytoskeleton,” The Journal of Biological Chemistry, vol. 274, no. 50, pp. 35944–35949, 1999. View at Publisher · View at Google Scholar · View at Scopus
89. K. Nakahata, H. Kinoshita, Y. Tokinaga et al., “Vasodilation mediated by inward rectifier K+ channels in cerebral microvessels of hypertensive and normotensive rats,” Anesthesia and Analgesia, vol. 102, no. 2, pp. 571–576, 2006. View at Publisher · View at Google Scholar · View at Scopus
90. K. Takayama, K. I. Yuhki, K. Ono et al., “Thromboxane A2 and prostaglandin F2α mediate inflammatory tachycardia,” Nature Medicine, vol. 11, no. 5, pp. 562–566, 2005. View at Publisher · View at Google Scholar · View at Scopus
91. C. L. Alexander, S. J. Miller, and S. R. Abel, “Prostaglandin analog treatment of glaucoma and ocular hypertension,” Annals of Pharmacotherapy, vol. 36, no. 3, pp. 504–511, 2002. View at Scopus
92. Y. Sugimoto, A. Yamasaki, E. Segi et al., “Failure of parturition in mice lacking the prostaglandin F receptor,” Science, vol. 277, no. 5326, pp. 681–683, 1997. View at Publisher · View at Google Scholar · View at Scopus
93. M. D. Breyer and R. M. Breyer, “G protein-coupled prostanoid receptors and the kidney,” Annual Review of Physiology, vol. 63, pp. 579–605, 2001. View at Publisher · View at Google Scholar · View at Scopus
94. S. Basu, “Oxidative injury induced cyclooxygenase activation in experimental hepatotoxicity,” Biochemical and Biophysical Research Communications, vol. 254, no. 3, pp. 764–767, 1999. View at Publisher · View at Google Scholar · View at Scopus
95. S. Basu and M. Eriksson, “Oxidative injury and survival during endotoxemia,” FEBS Letters, vol. 438, no. 3, pp. 159–160, 1998. View at Publisher · View at Google Scholar · View at Scopus
96. S. Basu, M. Whiteman, D. L. Mattey, and B. Halliwell, “Raised levels of F2-isoprostanes and prostaglandin F2α in different rheumatic diseases,” Annals of the Rheumatic Diseases, vol. 60, no. 6, pp. 627–631, 2001. View at Publisher · View at Google Scholar · View at Scopus